| Primary |
| Phimosis |
50.0% |
| Urinary Retention |
50.0% |
|
| Haemorrhage |
50.0% |
| Sleep Disorder |
50.0% |
|
| Secondary |
| Product Used For Unknown Indication |
24.6% |
| Benign Prostatic Hyperplasia |
14.2% |
| Type 2 Diabetes Mellitus |
12.9% |
| Hypertension |
8.6% |
| Drug Use For Unknown Indication |
4.7% |
| Cardiovascular Disorder |
4.3% |
| Prostate Cancer |
4.3% |
| Hyperlipidaemia |
3.4% |
| Muscle Spasms |
3.4% |
| Prostatomegaly |
3.4% |
| Pollakiuria |
3.0% |
| Dysuria |
1.7% |
| Nocturia |
1.7% |
| Prophylaxis |
1.7% |
| Prostatitis |
1.7% |
| Renal Failure Chronic |
1.7% |
| Angina Pectoris |
1.3% |
| Hypokalaemia |
1.3% |
| Arrhythmia |
0.9% |
| Asthma |
0.9% |
|
| Hepatic Function Abnormal |
8.3% |
| Red Blood Cell Count Decreased |
8.3% |
| Retrograde Ejaculation |
8.3% |
| Erectile Dysfunction |
5.6% |
| Fatigue |
5.6% |
| Functional Gastrointestinal Disorder |
5.6% |
| Injection Site Swelling |
5.6% |
| Peripheral Arterial Occlusive Disease |
5.6% |
| Peripheral Coldness |
5.6% |
| Pneumonitis |
5.6% |
| Torsade De Pointes |
5.6% |
| Urinary Incontinence |
5.6% |
| White Blood Cell Count Increased |
5.6% |
| Drooling |
2.8% |
| Drug Ineffective |
2.8% |
| Feeling Abnormal |
2.8% |
| Malaise |
2.8% |
| Multiple Drug Overdose Intentional |
2.8% |
| Pneumonia |
2.8% |
| Respiratory Failure |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.0% |
| Benign Prostatic Hyperplasia |
7.5% |
| Nuclear Magnetic Resonance Imaging |
6.7% |
| Hypertension |
6.4% |
| Drug Use For Unknown Indication |
5.5% |
| Adverse Event |
4.1% |
| Depression |
4.0% |
| Dysuria |
3.8% |
| Colorectal Cancer |
3.7% |
| Constipation |
3.3% |
| Diabetes Mellitus |
3.0% |
| Chronic Myeloid Leukaemia |
2.9% |
| Prostate Cancer Stage Iv |
2.7% |
| Back Pain |
2.6% |
| Multiple Sclerosis |
2.1% |
| Plasma Cell Myeloma |
2.0% |
| Atrial Fibrillation |
1.7% |
| Bladder Cancer |
1.7% |
| Prophylaxis |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.7% |
|
| White Blood Cell Count Decreased |
13.7% |
| Cerebral Infarction |
8.2% |
| Fatigue |
8.2% |
| Hepatic Function Abnormal |
8.2% |
| Thrombocytopenia |
6.8% |
| Weight Decreased |
6.8% |
| Prostate Cancer Stage Iv |
5.5% |
| Benign Prostatic Hyperplasia |
4.1% |
| Dysuria |
4.1% |
| Rash |
4.1% |
| Urinary Retention |
4.1% |
| White Blood Cell Count Increased |
4.1% |
| Aspartate Aminotransferase Increased |
2.7% |
| Cardiac Failure |
2.7% |
| Cerebral Haemorrhage |
2.7% |
| Disorientation |
2.7% |
| Dizziness |
2.7% |
| Drug Ineffective |
2.7% |
| Dyspnoea |
2.7% |
| Hyperkalaemia |
2.7% |
|
| Interacting |
| Benign Prostatic Hyperplasia |
10.5% |
| Hypertension |
10.5% |
| Pneumonia Bacterial |
10.5% |
| Angina Pectoris |
5.3% |
| Arrhythmia |
5.3% |
| Asthma |
5.3% |
| Blood Pressure |
5.3% |
| Depression |
5.3% |
| Hyperlipidaemia |
5.3% |
| Product Used For Unknown Indication |
5.3% |
| Prophylaxis |
5.3% |
| Prostate Cancer |
5.3% |
| Surgery |
5.3% |
| Erectile Dysfunction |
2.6% |
| Hypertrophy |
2.6% |
| Metastatic Renal Cell Carcinoma |
2.6% |
| Obesity |
2.6% |
| Pollakiuria |
2.6% |
| Prostatomegaly |
2.6% |
|
| Drug Ineffective |
25.0% |
| Drug Interaction |
25.0% |
| Pollakiuria |
12.5% |
| Thrombocytopenia |
12.5% |
| Torsade De Pointes |
12.5% |
| Ventricular Tachycardia |
12.5% |
|
